NEU.AX
Price:
$19.59
Market Cap:
$2.44B
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Industry
Biotechnology
IPO Date
2005-02-01
Stock Exchange
ASX
Ticker
NEU.AX
According to Neuren Pharmaceuticals Limited’s latest financial reports and current stock price. The company's current ROE is 43.38%. This represents a change of 76.37% compared to the average of 24.60% of the last 4 quarters.
The mean historical ROE of Neuren Pharmaceuticals Limited over the last ten years is -36.76%. The current 43.38% ROE has changed -218.01% with respect to the historical average. Over the past ten years (40 quarters), NEU.AX's ROE was at its highest in in the December 2023 quarter at 53.25%. The ROE was at its lowest in in the June 2017 quarter at -361.71%.
Average
-36.76%
Median
-9.71%
Minimum
-287.21%
Maximum
76.55%
Discovering the peaks and valleys of Neuren Pharmaceuticals Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 17.20%
Maximum Annual ROE = 76.55%
Minimum Annual Increase = -727.05%
Minimum Annual ROE = -287.21%
| Year | ROE | Change |
|---|---|---|
| 2024 | 39.03% | -49.01% |
| 2023 | 76.55% | 17.20% |
| 2022 | 0.44% | -102.23% |
| 2021 | -19.86% | -47.73% |
| 2020 | -37.99% | -51.37% |
| 2019 | -78.11% | -727.05% |
| 2018 | 12.46% | -38.00% |
| 2017 | 20.09% | -107.00% |
| 2016 | -287.21% | 208.76% |
| 2015 | -93.02% | 116.37% |
The current ROE of Neuren Pharmaceuticals Limited (NEU.AX) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
38.67%
5-year avg
11.64%
10-year avg
-36.76%
Neuren Pharmaceuticals Limited’s ROE is greater than Mesoblast Limited (-15.13%), less than Summerset Group Holdings Limited (11.88%), greater than Clarity Pharmaceuticals Ltd (-59.10%), greater than Regis Healthcare Limited (-286.21%), less than Clinuvel Pharmaceuticals Limited (15.79%), greater than Immutep Limited (-38.87%), greater than Alterity Therapeutics Limited (-48.41%), greater than Botanix Pharmaceuticals Limited (-99.43%), less than EZZ Life Science Holdings Limited (25.82%), greater than PYC Therapeutics Limited (-44.71%),
| Company | ROE | Market cap |
|---|---|---|
| -15.13% | $3.73B | |
| 11.88% | $2.43B | |
| -59.10% | $1.24B | |
| -286.21% | $2.20B | |
| 15.79% | $663.15M | |
| -38.87% | $581.41M | |
| -48.41% | $81.32M | |
| -99.43% | $236.24M | |
| 25.82% | $68.17M | |
| -44.71% | $874.89M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Neuren Pharmaceuticals Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Neuren Pharmaceuticals Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Neuren Pharmaceuticals Limited's ROE?
How is the ROE calculated for Neuren Pharmaceuticals Limited (NEU.AX)?
What is the highest ROE for Neuren Pharmaceuticals Limited (NEU.AX)?
What is the 3-year average ROE for Neuren Pharmaceuticals Limited (NEU.AX)?
What is the 5-year average ROE for Neuren Pharmaceuticals Limited (NEU.AX)?
How does the current ROE for Neuren Pharmaceuticals Limited (NEU.AX) compare to its historical average?